BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts
Rhea-AI Summary
BioLineRx (NASDAQ: BLRX) and Hemispherian reported new preclinical data on GLIX1 in glioblastoma (GBM). Orally administered GLIX1 showed dose-dependent anti-tumor activity in three orthotopic cell-derived xenograft models, with tumor growth inhibition and survival benefit across all doses.
In a new subcutaneous temozolomide (TMZ)-resistant patient-derived xenograft model, GLIX1 produced a robust anti-tumor effect while TMZ showed no effect, supporting the ongoing Phase 1/2a trial in recurrent and progressive GBM and other high-grade gliomas.
AI-generated analysis. Not financial advice.
Positive
- GLIX1 showed dose-dependent anti-tumor activity in three orthotopic GBM CDX models
- Tumor growth inhibition and survival benefit observed across all GLIX1 dose levels
- GLIX1 demonstrated robust anti-tumor effect in TMZ-resistant GBM PDX model
- Temozolomide showed no effect in the TMZ-resistant PDX model while GLIX1 did
- Preclinical dose-response data may help optimize dosing in the Phase 2 component
- New results further support the ongoing Phase 1/2a GLIX1 GBM trial
Negative
- Evidence so far is preclinical; clinical efficacy outcomes for GLIX1 are not yet reported
- Phase 1/2a GLIX1 trial for recurrent GBM and high-grade gliomas is still in early stages
News Market Reaction – BLRX
On the day this news was published, BLRX declined 5.90%, reflecting a notable negative market reaction. Argus tracked a peak move of +21.1% during that session. Argus tracked a trough of -28.5% from its starting point during tracking. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $783K from the company's valuation, bringing the market cap to $12.49M at that time. Trading volume was exceptionally heavy at 50.5x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
While BLRX was down 6.21%, peers showed mixed moves: MTVA up 70.27000188827515%, EDSA up 6.150000169873238%, and others like PRTG down 10.39%. This divergence points to stock-specific trading rather than a uniform biotech move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 28 | Clinical trial update | Positive | +17.7% | First patient dosed in Phase 1/2a GLIX1 GBM trial. |
| Apr 08 | Clinical trial start | Positive | +1.3% | Hemispherian initiated first-in-human Phase 1/2a GLIX1 trial. |
| Mar 26 | Clinical trial start | Positive | -2.1% | BioLineRx announced initiation of GLIX1 Phase 1/2a GBM study. |
| Mar 23 | Earnings and update | Positive | -12.4% | 2025 results with $20.9M cash and reduced net loss vs 2024. |
| Mar 16 | Earnings date notice | Neutral | -4.1% | Announcement of date and call for 2025 annual results. |
Recent GLIX1 clinical trial headlines often produced positive but inconsistent price reactions, while earnings-related items have sometimes seen negative follow-through.
Over the last few months, BLRX has focused on advancing GLIX1 for glioblastoma. On Mar 26, 2026, it initiated the Phase 1/2a study, followed by Hemispherian’s trial initiation update on Apr 8, 2026 and first-patient-dosed news on Apr 28, 2026, which saw a 17.73% gain. The Mar 23, 2026 2025 results highlighted $20.9 million in cash and reduced net loss yet coincided with a -12.45% move. Today’s preclinical data further build the GLIX1 story against this backdrop.
Market Pulse Summary
The stock moved -5.9% in the session following this news. The decline reflects a divergence between encouraging preclinical data and existing market skepticism. Shares were already 64.03% below the $7.7699 52-week high and trading under the $3.19 200-day MA, suggesting a fragile technical backdrop. Past GLIX1 updates have sometimes led to gains, like the 17.73% move on first-patient dosing, but other catalysts and earnings news saw negative reactions, underscoring execution and funding risks that could weigh on sentiment.
Key Terms
glioblastoma (gbm) medical
orthotopic cell-derived xenograft (cdx) medical
patient-derived xenograft (pdx) medical
temozolomide (tmz) medical
phase 1/2a medical
dna damage repair medical
AI-generated analysis. Not financial advice.
New preclinical data further demonstrate GLIX1's robust efficacy in a dose-dependent manner, with strong anti-tumor activity observed even at the lowest doses tested
Results highlight GLIX1's potential to address the high unmet need for patients with GBM
GBM remains one of the most aggressive and treatment-resistant cancers, urgently in need of breakthrough innovations and more effective treatment.
In a comprehensive pre-clinical program, orally administered GLIX1 demonstrated robust anti-tumor activity in orthotopic cell-derived xenograft (CDX) GBM models, as well as in a newly completed subcutaneous TMZ-resistant patient-derived xenograft (PDX) GBM model. In the three orthotopic CDX studies, significant tumor growth inhibition and survival benefit were observed following treatment with GLIX1 across all doses tested, with greater benefit at higher dose levels. In these models, mice treated with TMZ also showed significantly decreased tumor volume and survival benefit. Most notably, in the subcutaneous PDX model, GLIX1 demonstrated a robust anti-tumor effect while TMZ showed no effect.
"The compelling results from these studies, including the recently completed TMZ-resistant PDX model, are very exciting as they suggest that GLIX1 may bring hope to a broad range of patients with GBM," said Philip Serlin, Chief Executive Officer of BioLineRx. "In addition, the pre-clinical dose-response characterization adds important information for dose optimization in the Phase 2 part of the ongoing clinical study. We believe GLIX1 has the potential to offer a novel therapeutic approach in this cancer indication, as well as in multiple other cancer indications where DNA damage repair is critical for cancer survival."
BioLineRx and Hemispherian plan to present the data from these studies at one or more future medical conferences.
About Glioblastoma
Glioblastoma is the most common primary brain tumor and remains one of the most aggressive and treatment-resistant cancers, urgently in need of breakthrough innovations and more effective treatment. The standard of care for newly diagnosed GBM established since 2005 consists of surgery, followed by radiotherapy and treatment with temozolomide (TMZ), with no established standard of care for recurrent GBM. However, patients with unmethylated MGMT[1] promoter status (who represent more than half of all GBM patients) have demonstrated a limited response to TMZ.
About GLIX1
GLIX1 is a first-in-class, orally administered, brain penetrating, small molecule activator of the Ten-Eleven Translocation 2 (TET2) pathway that is commonly inhibited in cancer. Activating the novel TET2 pathway by GLIX1 overwhelms the DNA repair capacity of cancer cells, resulting in apoptotic cancer cell death.
About the Phase 1/2a Trial with GLIX1
The Phase 1/2a trial is an open-label, multicenter trial. Part 1 of the trial is a dose escalation study where patients receive GLIX1 daily as monotherapy. This part is expected to recruit up to 30 patients with recurrent and progressive GBM and other high-grade gliomas. The primary objective is to establish a maximum tolerated dose (MTD) and/or a recommended dose based on safety, PK/PD and preliminary efficacy. Updates to the Phase 1/2a trial are anticipated during H2 2026, with full results on the dose escalation part expected in 2027.
The Phase 2a expansion part of the trial is planned to include additional indications, including newly diagnosed GBM, as well as select cancers, with GLIX1 as monotherapy or in combination with standard of care (including in combination with PARP inhibitors). These cohorts are expected to identify preliminary efficacy, PD assessments and dose optimization data, serving as the basis for a rapid and effective advanced clinical development plan.
For more information on the Phase 1/2a trial, please visit NCT07464925.
[1] MGMT stands for O6-methylguanine-DNA methyltransferase, a DNA repair enzyme.
About Hemispherian
Hemispherian AS is a clinical-stage pharmaceutical company developing first-in-class small-molecule cancer therapies. Its lead program, GLIX1, is being advanced in partnership with BioLineRx for the treatment of glioblastoma and a broad range of solid tumors.
The company is headquartered in
Learn more at www.hemispherian.com or on LinkedIn.
About BioLineRx
BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The Company's lead development asset is GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other solid tumors, for which a Phase 1/2a clinical trial has been initiated in the first quarter of 2026. GLIX1 is being developed under a collaboration with Hemispherian AS.
The Company's first approved product, APHEXDA® (motixafortide), is indicated in the
Learn more about who we are, what we do, and how we do it at www.biolinerx.com, or on LinkedIn.
Forward Looking Statement
Various statements in this release concerning BioLineRx's future expectations constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," and "would," and describe opinions about future events. These include statements regarding management's expectations, beliefs and intentions regarding, among other things, the expectations with regard to the planned Phase 1/2a GLIX1 clinical trial, expected timing of a clinical readout, and BioLineRx's business strategy. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause BioLineRx's actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the clinical development, commercialization and market acceptance of GLIX1 and motixafortide including the degree and pace of market uptake of APHEXDA for the mobilization of hematopoietic stem cells for autologous transplantation in multiple myeloma patients; the initiation, timing, progress and results of BioLineRx's preclinical studies, clinical trials and other therapeutic candidate development efforts; BioLineRx's ability to advance GLIX1 and motixafortide into clinical trials or to successfully complete its preclinical studies or clinical trials; whether the clinical trial results for GLIX1 and motixafortide will be predictive of real-world results; BioLineRx's receipt of regulatory approvals for GLIX1 and motixafortide and the timing of other regulatory filings and approvals; whether access to GLIX1 and motixafortide is achieved in a commercially viable manner and whether GLIX1 and motixafortide receives adequate reimbursement from third.-party payors; BioLineRx's ability to establish, manage, and maintain corporate collaborations, as well as the ability of BioLineRx's collaborators to execute on their development and commercialization plans; BioLineRx's ability to integrate new therapeutic candidates and new personnel, as well as new collaborations; the interpretation of the properties and characteristics of BioLineRx's therapeutic candidates and of the results obtained with its therapeutic candidates in preclinical studies or clinical trials; the implementation of BioLineRx's business model and strategic plans for its business and therapeutic candidates; the scope of protection that BioLineRx's is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; estimates of BioLineRx's expenses, future revenues, capital requirements and its need for and ability to access sufficient additional financing; risks related to changes in healthcare laws, rules and regulations in
Logo - https://mma.prnewswire.com/media/2154863/BioLineRx_Ltd_Logo.jpg
Logo - https://mma.prnewswire.com/media/2966446/Hemispherian.jpg
Contacts:
For BioLineRx:
Chuck Padala
LifeSci Advisors, LLC
IR@biolinerx.com
Moran Meir
LifeSci Advisors, LLC
moran@lifesciadvisors.com
For Hemispherian AS:
Zeno Albisser, CEO
zeno@hemispherian.com
View original content:SOURCE BioLineRx Ltd.; Hemispherian AS